$AGIO insider trading
Over the last 12 months, Agios Pharmaceuticals insiders reported no purchases and 29 sales totaling $4.9M across SEC Form 4 filings. 97% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $4.9M 29 events
- Events · 12m
- 29 Form 4 filings, grouped
- Insiders · 12m
- 8 distinct reporters
- 10b5-1 share
- 97% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | Gheuens SarahChief Medical Officer · O | ▼ Sale | 30,000 | $30.48 | $914K | -35.4% | plan |
| Jul 1, 2026 | Gheuens SarahChief Medical Officer · O | ▼ Sale | 4,007 | $37.56 | $151K | -4.5% | plan |
| Apr 2, 2026 | Burns James WilliamChief Legal Officer · O | ▼ Sale | 3,280 | $34.71 | $114K | -6.2% | plan |
| Apr 2, 2026 | Gheuens SarahChief Medical Officer · O | ▼ Sale | 2,940 | $34.71 | $102K | -3.5% | plan |
| Apr 2, 2026 | Jones CeciliaChief Financial Officer · O | ▼ Sale | 3,141 | $34.71 | $109K | -5.4% | plan |
| Apr 2, 2026 | Milanova TsvetaChief Commercial Officer · O | ▼ Sale | 3,262 | $34.71 | $113K | -6.5% | plan |
| Apr 2, 2026 | Viswanadhan KrishnanChief Corp Dev & Strategy · O | ▼ Sale | 2,959 | $34.71 | $103K | -22.3% | plan |
| Apr 2, 2026 | Goff BrianChief Executive Officer · O·D | ▼ Sale | 19,068 | $34.71 | $662K | -9.4% | plan · 2 tranches |
| Mar 5, 2026 | Viswanadhan KrishnanChief Corp Dev & Strategy · O | ▼ Sale | 2,959 | $27.8 | $82K | -36.5% | plan |
| Mar 3, 2026 | Washburn Theodore James Jr.Principal Accounting Officer · O | ▼ Sale | 5,272 | $28.88 | $152K | -85.9% | — |
| Mar 2, 2026 | Goff BrianChief Executive Officer · O·D | ▼ Sale | 18,055 | $28.96 | $523K | -9.9% | plan · 3 tranches |
| Mar 2, 2026 | Burns James WilliamChief Legal Officer · O | ▼ Sale | 5,218 | $28.96 | $151K | -10.6% | plan · 4 tranches |
| Mar 2, 2026 | Gheuens SarahChief Medical Officer · O | ▼ Sale | 4,055 | $28.96 | $117K | -5.2% | plan · 3 tranches |
| Mar 2, 2026 | Jones CeciliaChief Financial Officer · O | ▼ Sale | 5,035 | $28.96 | $146K | -9.3% | plan · 4 tranches |
| Mar 2, 2026 | Milanova TsvetaChief Commercial Officer · O | ▼ Sale | 2,868 | $28.96 | $83K | -6.5% | plan · 2 tranches |
| Mar 2, 2026 | Washburn Theodore James Jr.Principal Accounting Officer · O | ▼ Sale | 2,223 | $28.96 | $64K | -26.6% | plan · 3 tranches |
| Jan 5, 2026 | Milanova TsvetaChief Commercial Officer · O | ▼ Sale | 2,872 | $27.02 | $78K | -7.6% | plan |
| Dec 30, 2025 | Burns James WilliamChief Legal Officer · O | ▼ Sale | 2,932 | $27.09 | $79K | -8.5% | plan |
| Dec 30, 2025 | Goff BrianChief Executive Officer · O·D | ▼ Sale | 18,703 | $27.09 | $507K | -11.6% | plan · 2 tranches |
| Dec 30, 2025 | Gheuens SarahChief Medical Officer · O | ▼ Sale | 2,932 | $27.09 | $79K | -4.3% | plan |
| Dec 30, 2025 | Milanova TsvetaChief Commercial Officer · O | ▼ Sale | 2,932 | $27.09 | $79K | -9.1% | plan |
| Dec 30, 2025 | Jones CeciliaChief Financial Officer · O | ▼ Sale | 2,932 | $27.09 | $79K | -7.3% | plan |
| Nov 12, 2025 | Scadden DavidD | ▼ Sale | 200 | $43.84 | $9K | -1.1% | plan |
| Nov 11, 2025 | Gheuens SarahChief Medical Officer · O | ▼ Sale | 2,454 | $43.78 | $107K | -3.8% | plan |
| Oct 30, 2025 | Gheuens SarahChief Medical Officer · O | ▼ Sale | 200 | $43.81 | $9K | -0.3% | plan |
| Oct 27, 2025 | Gheuens SarahChief Medical Officer · O | ▼ Sale | 3,302 | $43.92 | $145K | -5.1% | plan |
| Oct 8, 2025 | Scadden DavidD | ▼ Sale | 200 | $41 | $8K | -1.1% | plan |
| Sep 30, 2025 | Scadden DavidD | ▼ Sale | 200 | $40 | $8K | -1.1% | plan |
| Sep 26, 2025 | Jones CeciliaChief Financial Officer · O | ▼ Sale | 3,651 | $36.77 | $134K | -9.7% | plan |
| Sep 5, 2025 | Washburn Theodore James Jr.Principal Accounting Officer · O | ▼ Sale | 8,546 | $36.87 | $315K | -90.8% | — |
| Aug 27, 2025 | Scadden DavidD | ▼ Sale | 200 | $40 | $8K | -1.1% | plan |
| Aug 8, 2025 | Goff BrianChief Executive Officer · O·D | ▼ Sale | 11,085 | $36.67 | $406K | -8.2% | plan |
Every $AGIO filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Agios Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $AGIO feed.